Drugs / Pamapimod
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05659459 | Aug 2022 → Oct 2023 | COVID-19 | Kinarus AG | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pamapimod | “Combination Pamapimod 75mg with Pioglitazone 5mg” NCT05659459 ↗ |
| Known as | R-1503 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1090089 ↗ |
| Known as | RO 4402257 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1090089 ↗ |
| Action | Inhibit | “MAP kinase p38 alpha inhibitor” CHEMBL1090089 ↗ |
| Modality | Small molecule | — CHEMBL1090089 ↗ |
| Route | Oral | “Oral tablet” NCT05659459 ↗ |
| Target | MAPK14 | “MAP kinase p38 alpha inhibitor” CHEMBL1090089 ↗ |